Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril-Valsartan vs Enalapril in STEMI (PERI-STEMI)
NCT04912167Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacubitril + valsartan in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Left Ventricular Remodeling Index at 6 months. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT04912167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912167.